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Summary
We propose a computationally and statistically efficient divide-and-conquer (DAC) algorithm to
fit sparse Cox regression to massive datasets where the sample size n0 is exceedingly large and the
covariate dimension p is not small but n0  p. The proposed algorithm achieves computational
efficiency through a one-step linear approximation followed by a least square approximation to
the partial likelihood (PL). These sequences of linearization enable us to maximize the PL with
only a small subset and perform penalized estimation via a fast approximation to the PL. The
algorithm is applicable for the analysis of both time-independent and time-dependent survival
data. Simulations suggest that the proposed DAC algorithm substantially outperforms the full
sample-based estimators and the existing DAC algorithm with respect to the computational
speed, while it achieves similar statistical efficiency as the full sample-based estimators. The
proposed algorithm was applied to an extraordinarily large time-independent survival dataset
and an extraordinarily large time-dependent survival dataset for the prediction of heart failure-
specific readmission within 30 days among Medicare heart failure patients.
Key words: Divide-and-conquer; shrinkage estimation; variable selection; Cox proportional hazards model;
least square approximation.
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1. Introduction
Large datasets derived from health insurance claims and electronic health records are becoming
increasingly available for health care and medical research. These datasets serve as valuable
sources for the development of risk prediction models, which are the key components of precision
medicine. Fitting risk prediction models to a dataset with a massive sample size (n0), however,
is computationally challenging, especially when the number of candidate predictors (p) is also
large and yet only a small subset of the predictors are informative. In such a setting, it is highly
desirable to fit a sparse regression model to simultaneously remove non-informative predictors and
estimate the effects of the informative predictors. When the outcome of interest is time-to-event
and is subject to censoring, one may obtain a sparse risk prediction model by fitting a regularized
Cox proportional hazards model (Cox, 1972) with penalty functions such as the adaptive least
absolute shrinkage and selection operator (LASSO) penalty (Zhang and Lu, 2007).
When n0 is extraordinarily large, directly fitting an adaptive LASSO penalized Cox model
to such a dataset is not computationally feasible. To overcome the computational difficulty, one
may employ the divide-and-conquer (DAC) strategy, which typically divides the full sample into
subsets, solves the optimization problem using each subset, and combines the subset-specific
estimates into a combined estimate. Various DAC algorithms have been proposed to fit penalized
regression models. For example, Chen and Xie (2014) proposed a DAC algorithm to fit penalized
generalized linear models (GLM). The algorithm obtains a sparse GLM estimate for each subset
and then combines subset-specific estimates by majority voting and averaging. Tang and others
(2016) proposed an alternative DAC algorithm to fit GLM with an extremely large n0 and a
large p by combining de-biased LASSO estimates from each subset. While both algorithms are
effective in reducing the computation burden compared to fitting a penalized regression model to
the full data, they remain computationally intensive as K penalized estimation procedures will
be required. In addition, the DAC strategy has not been extended to the survival data analysis.
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In this paper, we propose a novel DAC algorithm using sequences of linearization, denoted
by DAClin, to fit adaptive LASSO penalized Cox proportional hazards models, which can further
reduce the computation burden compared to the existing DAC algorithms. DAClin starts with
obtaining an estimator that maximizes the partial likelihood (PL) of a subset of the full data,
which is then updated using all subsets via one-step approximations. The updated estimator
serves as a
√
n0-consistent initial estimator for the adaptive LASSO problem and approximates
the full sample-based maximum PL estimator. Subsequently, we obtain the final adaptive LASSO
estimator based on an objective function applying the least square approximation (LSA) to the
PL as in Wang and Leng (2007). The LSA allows us to fit the adaptive LASSO using a pseudo
likelihood based on a sample of size p. The penalized regression is only fit once in the proposed
DAClin algorithm and the improvement in computation cost is substantial if n0  p. Our proposed
DAClin algorithm can also accommodate time-dependent covariates.
The rest of the paper is organized as follows. We detail the DAClin algorithm in section 2.
In section 3, we present simulation results demonstrating the superiority of DAClin compared to
the existing methods when covariates are time-independent and when some covariates are time-
dependent. In section 4, we employ the DAClin algorithm to develop risk prediction models for
30-day readmission after an index heart failure hospitalization with data from over 10 million
Medicare patients by fitting regularized Cox models with (i) p = 540 time-independent covari-
ates and (ii) pind = 575 time-independent covariates and pdep = 5 time-dependent environmental
covariates. We conclude with some discussions in section 5.
2. Methods
2.1 Notation and Settings
Let T denote the survival time and Z(·) denote the p × 1 vector of bounded and potentially
time-dependent covariates. Due to censoring, for T , we only observe (X,∆), where X = T ∧ C,
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∆ = I(T 6 C), and C is the censoring time assumed to be independent of T given Z(·). Suppose
the data for analysis consist of n0 subjects with independent realizations of D = (X,∆,Z(·)T)T,
denoted by Dfull = {Di = (Xi,∆i,Zi(·)T)T, i = 1, ..., n0}, where we assume that n0  p.
We denote the index set for the full data by Ωfull = {1, ..., n0}. For all DAC algorithms discussed
in this paper, we randomly partition Dfull into K subsets with the k-th subset denoted by Dk =
{Di, i ∈ Ωk}. Without loss of generality, we assume that n = n0/K is an integer and that the
index set for the subset k is Ωk = {(k − 1)n + 1, ..., kn}. For any index set Ω, we denote the
size of Ω by nΩ with nΩ = n0 if Ω = Ωfull and nΩ = n if Ω = Ωk. Throughout we assume that
K = o
(
n
1
2
0
)
such that n−1 = o
(
n
− 12
0
)
and n p.
To develop a risk prediction model for T based on Z(·), we consider the Cox model,
λ(t|Z(t)) = λ0(t) exp (βT0Z(t)) , (2.1)
where λ(t|Z(t)) is the conditional hazard function and λ0(t) is the baseline hazard function. Our
goal is to develop a computationally and statistically efficient procedure to estimate β0 using data
in Dfull under the assumption that β0 is sparse with the size of the active set A = { : β0 6= 0}
much smaller than p.
When n0 is not extraordinarily large, we may obtain an efficient estimate, denoted by β̂full,
based on the adaptive LASSO penalized PL likelihood estimator as proposed in Zhang and Lu
(2007). Specifically,
β̂full = argmax
β
{̂`
Ωfull(β)− λΩfull
p∑
ι=1
|βι|
|β˜ι,init|γ
}
(2.2)
where for any index set Ω,
̂`
Ω(β) = n
−1
Ω
∑
i∈Ω
`i(β), `i(β) = ∆i
[
βTZi(Xi)− log
{∑
i′∈Ω
I(Xi′ > Xi)eβ
TZi′ (Xi′ )
}]
, (2.3)
β˜init = (β˜1,init, · · · , β˜p,init)′ is an initial
√
n0-consistent estimator of model (2.1), λΩfull > 0 is a
tuning parameter, and γ > 0. A simple choice of β˜init is β˜Ωfull , where for any set Ω,
β˜Ω = argmax
β
̂`
Ω(β).
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Following the arguments given in Zhang and Lu (2007), when n
1
2
0 λΩfull → 0 and n(1+γ)/20 λΩfull →∞,
we can show that β̂full achieves the variable selection consistency, i.e. the estimated active set
Âfull = { : β̂ full, 6= 0} satisfies P (Âfull = A)→ 1 and that the oracle property holds, i.e.
n
1
2
0 (β̂
A
full−β0) = ÂAΩfull(β0)−1n
1
2
0 Û
A
Ωfull
(β0)+op(1) = AA(β0)−1n
1
2
0 Û
A
Ωfull
(β0)+op(1)
D−→ N (0,AA(β0)−1) ,
where for any set A, GA = {Gl, l ∈ A} if G is a vector and GA = [Wll′ ]l∈A,l′∈A if G is a matrix,
A(β) =
∫ S2(t,β)S0(t,β)− S1(t,β)⊗2
S0(t,β)2 dE{Ni(t)}, ÂΩ(β) = −
∂2 ̂`Ω(β)
∂β∂βT
ÛΩ(β) = n
−1
Ω
∑
i∈Ω Ûi,Ω(β), Sr(t,β) = E{Zi(t)⊗rI(Xi > t)}, Ŝr,Ω(t,β) = n−1Ω
∑
i∈Ω Zi(t)
⊗rI(Xi >
t), Ûi,Ω(β) =
∫ {Zi(t) − Ŝ1,Ω(t,β)/Ŝ0,Ω(t,β)}dMi(t,β), Ni(t) = I(Ti 6 t)∆i, Mi(t,β) =
Ni(t)−
∫ t
0
I(Xi > u)eβ
TZi(u)λ0(u)du, a
⊗0 = 1, a⊗1 = a and a⊗2 = aaT for any vector a.
When n0 is not too large, multiple algorithms are available to solve (2.2) with time-independent
covariates, including a gradient descent algorithm (Simon and others, 2011), a least angle regres-
sion (LARS)-like algorithm (Park and Hastie, 2007), a combination gradient descent-Newton
Raphson method (Goeman, 2010), and a modified shooting algorithm (Zhang and Lu, 2007).
Unfortunately, when n0 is extraordinarily large, none of the existing algorithms for (2.2) will
be computationally feasible. While these algorithms may be extended to fit sparse Cox models
with time-dependent covariates, the computation is even more demanding since each subject may
contribute multiple observations in the fitting.
2.2 The DAClin Algorithm
The goal of this paper is to develop an estimator that achieves the same asymptotic efficiency as
β̂full but can be computed very efficiently.
Our proposed algorithm, DAClin, for attaining such a property is motivated by the LSA pro-
posed in Wang and Leng (2007), with the LSA applied to the full sample-based PL. Specifically,
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it is not difficult to show that β̂full is asymptotically equivalent to β̂full,lin, where
β̂full,lin = argmin
β
1
2
(β˜Ωfull − β)TÂΩfull(β˜Ωfull)(β˜Ωfull − β) + λn0
p∑
ι=1
|βι|
|β˜ι,Ωfull |γ
That is, β̂full,lin will also achieve the variable selection consistency as β̂full and β̂
A
full,lin has the same
limiting distribution as that of β̂
A
full. This suggests that an estimator can recover the distribution
of β̂full if we can construct an accurate DAC approximations to β˜Ωfull and ÂΩfull(β˜Ωfull). To this end,
we propose a linearization-based DAC estimator, denoted by β̂DAC, which requires three main
steps: (i) obtaining an estimator for the unpenalized problem β˜
[0]
DAC based on a subset, say D1;
(ii) obtaining updated estimators for the unpenalized problem through one-step approximations
using all K subsets; and (iii) constructing an adaptive LASSO penalized estimator based on LSA.
The procedure also brings a ÂDAC(β˜DAC) that well approximates ÂΩfull(β˜Ωfull).
Specifically, in step (i), we use subset D1 to obtain a standard maximum PL estimator,
step (i) β˜
[0]
DAC ≡ β˜Ω1 = argmax
β
̂`
Ω1(β).
In step (ii), we obtain a DAC one-step approximation to β˜Ωfull ,
step (ii) for ι = 1, ..., I, β˜[ι]DAC = K−1
K∑
k=1
β˜Ωk,lin(β˜
[ι−1]
DAC )
where
β˜Ωk,lin(β) = β + ÂDAC(β)
−1ÛΩk(β) and ÂDAC(β) = K−1
K∑
k=1
ÂΩk(β). (2.4)
Let β˜DAC = β˜
[I]
DAC be our DAC approximation to β˜Ωfull . In practice, we find that it suffices to let
I = 2. Finally, we apply the LSA to the PL and approximate β̂full using β̂DAC, where
step (iii) β̂DAC = argmin
β
{
1
2
(β˜DAC − β)TÂDAC(β˜DAC)(β˜DAC − β) + λΩfull
p∑
=1
|β|
|β˜DAC,|γ
}
.
The optimization problem in step (iii) is equivalent to
β̂DAC = argmin
β
{
1
2
(Y˜0(β˜DAC)− X˜0(β˜DAC)β)T(Y˜0(β˜DAC)− X˜0(β˜DAC)β) + λΩfull
p∑
=1
|β|
|β˜DAC,|γ
}
(2.5)
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where Y˜0(β˜DAC) = ÂDAC(β˜DAC)
1
2 β˜DAC is a p×1 vector and X˜0(β˜DAC) = ÂDAC(β˜DAC)
1
2 is a p×p matrix.
The linearization allows us to solve the penalized regression step using a pseudo likelihood based
on a sample of size p. The computation cost of this step compared to solving (2.2) reduces
substantially when n0  p. In the Appendix, we show that n
1
2
0 (β˜DAC−β˜Ωfull) = op(1). It then follows
from the similar arguments given in Wang and Leng (2007) that if n
1
2
0 λn0 → 0, n(1+γ)/20 λn0 →∞,
the estimated active set using DAClin ÂDAC achieves the variable selection consistency, i.e. P (ÂDAC =
A)→ 1 and the oracle property holds, i.e. β̂ADAC and β̂
A
full have the same limiting distribution.
2.3 Tuning and Standard Error Calculation
The tuning parameter λΩfull is chosen by minimizing the Bayesian information criteria (BIC) of
the fitted model. Volinsky and Raftery (2000) showed that the exact Bayes factor can be better
approximated for the Cox model if the number of uncensored cases, d0 =
∑
i∈Ωfull ∆i, is used to
penalize the degrees of freedom in the Bayesian Information Criteria (BIC). Specifically, for any
given tuning parameter λΩfull with its corresponding estimate of β, β̂λΩfull
, the BIC suggested by
Volinsky and Raftery (2000) is defined as
BICV,λΩfull = −2
∑
i∈Ωfull
`i(β̂λΩfull
) + (log d0)dfλΩfull , (2.6)
where dfλΩfull =
∑p
=1 I(β̂λΩfull , 6= 0). With the LSA, we may further approximate BICV,λΩfull by
BICVL,λΩfull = n0(β̂DAC − β̂λΩfull )
TÂDAC(β˜DAC)(β̂DAC − β̂λΩfull ) + (log d0)dfλΩfull . (2.7)
For the estimation of β̂DAC, we chose a λΩfull such that BICVL,λΩfull is minimized. The oracle
property is expected to hold in the setting where n0  p and n0 is extraordinarily large. We may
thus estimate the variance-covariance matrix for n
1
2
0 (β̂
A
DAC − βA0 ) using ÂA(β˜DAC)−1. For  ∈ A, a
(1− α)× 100% confidence interval for β0 can be calculated accordingly.
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3. Simulations
3.1 Simulation Settings
We performed two sets of simulations to evaluate the performance of β̂DAC for the fitting of
sparse Cox models, one with only time-independent covariates and the other with time-dependent
covariates. For both scenarios, we let n0 = 1, 000, 000 and K = 100. We consider the number of
iterations I = 1, 2, and 3 to examine the impact of I on the proposed estimator.
3.1.1 Time-independent covariates We conducted extensive simulations to evaluate the perfor-
mance of the proposed estimator β̂DAC relative to (a) the performance of the full sample-based
adaptive LASSO estimator for the Cox model β̂full and (b) a majority voting-based DAC method
for the Cox model, denoted by β̂MV also with K = 100, penalized by a minimax concave penalty
(MCP), which extends the majority voting-based DAC scheme for GLM proposed by Chen and
Xie (2014). The reason of choosing β̂MV as a comparison is that there is no other DAC method
available for the Cox model and only Chen and Xie (2014) considered a similar majority voting-
based DAC method for the penalized GLM with non-adaptive penalties. We set a priori that β̂MV
sets the estimate of a coefficient at zero, if at least 50% of the subset-specific estimates have a zero
estimate for that coefficient. In addition, we compared the performance of the DAC estimator
β˜DAC relative to the full sample maximum PL estimator β˜Ωfull .
For the penalized procedures, we selected the tuning parameter based on the BIC criterion
discussed in section 2.3. The adaptive LASSO procedures were fit using the glmnet function in
R with γ = 1; the MCP procedures were fit using the ncvsurv function in R.
For the covariates, we considered p = 50 and p = 200. We generated Z from a multivariate nor-
mal distribution with mean 0Tp and variance-covariance matrix V = [I(l = l′)+vI(l 6= l′)]l
′=1,...,p
l=1,...,p ,
where aq denotes a q × 1 vector with all elements being a and we considered v = 0.2, 0.5,
and 0.8 to represent weak, moderate, and strong correlations among the covariates. For a given
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Zi, i = 1, · · · , n0, we generated Ti from a Weibull distribution with a shape parameter of 2
and a scale parameter of {0.5 exp(βT0Zi)}−0.5, where we considered three choices of β0 to reflect
different degrees of sparsity and signal strength:
β
(I)
0 = (0.8
T
3,0.4
T
3,0.2
T
3,0
T
p−9)
T,
β
(II)
0 = (0.4
T
4,0.2
T
4,0.1
T
4,0.05
T
4,0
T
p−9)
T, and
β
(III)
0 = (1, 0.5,0.2
T
2,0.1
T
2,0.05
T
2,0.035
T
3,0p−11)
T.
For censoring, we generated C from an exponential distribution with a rate parameter of exp(0.5),
resulting in 68% ∼ 76% of censoring across different configurations.
3.1.2 Time-dependent covariates We also conducted simulations for the settings where time-
dependent covariates are present to evaluate the performance of β̂DAC. Since neither glmnet nor
ncvsurv allows time-dependent survival data, we used β̂full,lin as a benchmark to compare β̂DAC
with. In addition, we compared the performance of β˜DAC relative to β˜Ωfull .
We considered p = 100 consisting of pind = 50 time-independent covariates and pdep = 50
time-dependent covariates. The simulation of the survival data with time-dependent covariates
extended the simulation scheme of Austin (2012) from dichotomous time-dependent covariates
to continuous time-dependent covariates. We considered four time intervals R1 = [0, 1), R2 =
[1, 2), R3 = [2, 3), and R4 = [3,∞), where the time-dependent covariates are constant within
each interval but can vary between intervals. We generated Z = (ZTind,Zdep(t ∈ R1)T,Zdep(t ∈
R2)
T,Zdep(t ∈ R3)T,Zdep(t ∈ R4)T)T from a multivariate normal distribution with mean 0Tpind+4pdep
and variance-covariance matrix V = [I(l = l′) + vI(l 6= l′)]l′=1,...,pind+4pdepl=1,...,pind+4pdep , where Zind are the
time-independent covariates and Zdep(t ∈ R) are the time-dependent for t ∈ R. We similarly
considered v = 0.2, 0.5, 0.8 to represent weak, moderate, and strong correlations.
We generated Ti from a Weibull distribution with a shape parameter of 2 and a scale parameter
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of {0.05 exp(βT0Zi(t))}−0.5, where β(IV)0 = (β(IV)
T
ind,0 ,β
(IV)T
dep,0 )
T,
β(IV)ind,0 = (0.08
T
3,0.04
T
3,0.02
T
3,0
T
pind−9)
T, and β(IV)dep,0 = (0.08
T
3,0.04
T
3,0.02
T
3,0
T
pdep−9)
T.
We considered an administrative censoring with Ci = 4, leading to 44% censoring under the three
scenarios represented by weak, moderate, and strong correlations of the design matrix.
3.1.3 Measures of performance For any β̂ ∈ {β̂DAC, β̂full, β̂full,lin, β̂MV}, we report (a) the average
computation time for β̂; (b) the global mean squared error (GMSE), defined as (β̂−β0)TV(β̂−β0);
(c) empirical probability of  6∈ Â; (d) the bias of each individual coefficient; and (e) mean
squared error (MSE) of each individual coefficient. For β̂DAC and β̂full,lin, we also report the empirical
coverage level of the 95% normal confidence interval with standard error estimated as described
in section 2.3. For any β˜ ∈ {β˜DAC, β˜Ωfull}, we report (a) the average computation time for β˜; (b)
the global mean squared error (GMSE), defined as (β˜ − β0)TV(β˜ − β0).
The average computation time for each configuration is based on simulations using 50 simu-
lated datasets performed on Intel® Xeon® E5-2620 v3 @2.40GHz. The statistical performance
is evaluated based on 1000 simulated datasets for each configuration.
3.2 Simulation Results
We first show in Table 1 for the time-independent settings and in Table 2 for the time-dependent
settings the average computation time and GMSE of unpenalized estimators β˜DAC and β˜Ωfull . The
results suggest that β˜DAC with two iterations (I = 2) attains a GMSE comparable to the full
sample-based estimator β˜Ωfull and reduced the computation time by more than 50%. The DAC
estimator β˜DAC with two iterations (I = 2) has a similar GMSE to I = 3. Across all settings,
the results of β̂DAC are nearly identical with I = 2 or I = 3 and hence we summarize below the
results for β̂DAC only for I = 2 unless noted otherwise.
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3.2.1 Computation Time There are substantial differences in computation time across methods
(Table 3-6) for time-independent survival data. Across different settings, the average computation
time of β̂DAC ranges from 9.6 to 16.6 seconds for p = 50 and from 135.7 to 181.6 seconds for
p = 200, with virtually all time spent on the computation of the unpenalized estimator β˜DAC.
On the contrary, β̂full requires a substantially longer computation time with average time ranging
from 409.6 to 515.3 seconds for p = 50 and from 1435.0 to 1684.9 seconds for p = 200. This
suggests that the computation time of β̂DAC is about 2 − 3% of the full sample estimator when
p = 50 and about 10% when p = 200. On the other hand, β̂MV has a substantially longer average
computation time than β̂full. This is because the MCP procedure, requiring more computational
time than the adaptive LASSO, needs to be fitted K = 100 times.
In the presence of time-dependent covariates, Table 7 shows that β̂DAC has an average compu-
tation time of 112.3− 120.8 seconds for pind = 50 and pdep = 50; β̂full,lin has an average computation
time of 253.9− 263.5 seconds. Virtually all computation time for β̂DAC and β̂full,lin is spent on the
computation of the unpenalized initial estimator β˜DAC, which has more observations and requires
substantially more computation time compared to the setting with time-independent covariates
given the same n0 and p.
3.2.2 Statistical Performance The results for the simulation scenarios with only time-independent
covariates are summarized in Table 3-6. In general, β̂DAC is able to achieve a statistical performance
comparable to β̂full, while β̂MV generally has a worse performance, with respect to the GMSE and
variable selection, bias, and MSE of individual coefficient. For example, as shown in Table 3, the
GMSEs (×10−5) for β̂DAC, β̂full and β̂MV are respectively 4.27, 4.24, and 5.61 when p = 50 and
v = 0.2; 4.1, 4.08, 5.5 when p = 200 and v = 0.2. The relative performance of different pro-
cedures has similar patterns across different levels of correlation v among the covariates. When
the signals are relatively strong and sparse as for β0 = β
(I)
0 or β
(II)
0 , β̂DAC and β̂full have small
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biases and achieved perfect variable selection, while β̂MV substantially excludes the β0j = 0.05
signal when p = 200. For the more challenging case of β0 = β
(III)
0 where some of the signals are
weak, the variable selection of β̂DAC and β̂full is also near perfect. Both penalized estimators for the
weakest signal (0.035) exhibits a small amount of bias when v = 0.2 and 0.5 and an increased bias
when v = 0.8. Such biases in the weak signals are expected for shrinkage estimators (Menelaos
and others, 2016), especially in the presence of high correlation among covariates. However, it
is important to note that β̂DAC and β̂full perform nearly identically, suggesting that our DAClin
procedure incur negligible additional approximation errors. On the other hand, β̂MV has difficulty
in detecting the 0.05 and 0.035 signals and tends to produce substantially higher MSE than β̂DAC.
The empirical coverage levels for the confidence intervals are close to the nominal level across
all settings except for the very challenging set very weak signals when the correlation is v = 0.8.
This again is due to the bias inherent in shrinkage estimators..
The results for the time-dependent survival are summarized in Table 7. We find that β̂DAC
also generally has a good performance in estimating β
(IV)
0 for both time-independent and time-
dependent covariates. The variable selection consistency holds perfectly for all parameters of
interest. The coverage of the confidence intervals also has similar patterns as the case with time-
independent covariates.
4. Application of the DAC procedure to Medicare Data
We applied the proposed DAClin algorithm to develop risk prediction models for heart failure-
specific readmission or death within 30 days of discharge among Medicare patients who were
admitted due to heart failure. The Medicare inpatient claims were assembled for all Medicare
fee-for-service beneficiaries during 2000−2012 to identify the eligible study population. The index
date was defined as the discharge date of the first heart failure admission of each patient. We
restricted the study population to patients who were discharged alive from the first heart failure
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admission. The outcome of interest is time to heart failure-specific readmission or death after the
first heart failure admission. Because readmission rates within 30 days have been used to assess
the quality of care at hospitals by the Centers for Medicare and Medicaid Services (CMS) (CMS,
2016), we censored the time to readmission at 30 days. For a patient who were readmitted or
dead on the same day as discharge (whose claim did not indicate discharge dead), the time-to-
event was set at 0.5 days. Due to the large number of ICD-9 codes, we classified each discharge
ICD-9 code into disease phenotypes indexed by phenotype codes according to Denny and others
(2013). A heart failure admission or readmission was identified, if the claim for that admission
or readmission had a heart failure phenotype code at discharge.
We consider two sets of covariates: (I) time-independent covariates including baseline individual-
level covariates collected at time of discharge from the index heart failure hospitalization, baseline
area-level covariates at the residential ZIP code of each patient, and indicators for time trend
including include dummy variables for each year and dummy variables for each months, and
(II) time-dependent predictors that vary day-by-day. Baseline individual-level covariates include
age, sex, race (white, black, others), calendar year and month of the discharge, Charlson co-
morbidity index (CCI) (Quan and others, 2005) which describes the degree of illness of a patient,
and indicators for non-rare co-morbidities (defined as prevalence > 0.1 among the study popula-
tion). Baseline area-level covariates include socioeconomic status variables [percent black residents
(ranging from 0 to 1), percent Hispanic residents (ranging from 0 to 1), median household in-
come (per ten thousand increase), median home value (per ten thousand increase), percent below
poverty (ranging from 0 to 1), percent below high school (ranging from 0 to 1), percent owned
houses (ranging from 0 to 1)], population density (1000 per squared kilometer), and health status
variables [percent taking hemoglobin A1C test (ranging 0-1), average BMI, percent ambulance
use (ranging from 0 to 1), percent having low-density lipoprotein test (ranging from 0 to 1), and
smoke rate (ranging from 0 to 1)]. The time-dependent covariates include daily fine particulate
14 Y. Wang and others
matter (PM2.5) predicted using a neural network algorithm (Di and others, 2016), daily temper-
ature with its quadratic form, and daily dew point temperature with its quadratic form. There
were 574 time-independent covariates and 5 time-dependent covariates.
There were n0 = 9, 567, 752 eligible patients with a total of d0 = 2, 079, 436 heart failure
readmissions or deaths, among which 1, 453, 627 were readmissions and 625, 809 were deaths.
After expanding the dataset by accounting for time-dependent variables which vary day-by-day,
the time-dependent dataset contains 245, 623, 834 rows of records.
We fit cause-specific Cox models for readmission due to heart failure or deaths as a composite
outcome, considering two separate models: (i) a model containing only time-independent covari-
ates and (ii) a model incorporating time-dependent covariates. In both cases, the datasets are
too large for glmnet package to analyze as a whole, demonstrating the need for DAClin.
4.1 Time-independent Covariates Only
We applied DAClin with K = 50 and paralleled DAClin on 25 Authentic AMD Little Endian
@2.30GHz CPUs. Computing β̂DAC with I = 2 took 1.1 hours, including the time of reading
datasets from hard drives during each iteration of the update of the one-step estimator. Figure 1
shows the hazard ratio of each covariate based on β̂DAC with I = 2 predicting heart failure-specific
readmission and death within 30 days.
Multiple co-morbidities were associated with an increased risk of 30-day readmission or death
with the leading factors including renal failures, cancers, malnutrition, subdural or intracerebral
hemorrhage, myocardial infarction, endocarditis, respiratory failure, and cardiac arrest. CCI was
also associated with an increased hazard of the outcome. These findings are generally consistent
with those reported in the literature. For example, Philbin and DiSalvo (1999) reported that
ischemic heart disease, diabetes, renal diseases, and idiopathic cardiomyopathy were associated
with an increased risk of heart failure-specific readmission within a year. Leading factors nega-
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tively associated with readmissions included virus infections, asthma, and chronic kidney disease
in earlier stages. These negative association findings are reflective of both clinical practice pat-
terns and the biological effects, as most of the negative predictors are generally less severe than
the positive predictors.
Some socioeconomic status predictors were relatively less important in predicting the out-
come after accounting for the phenotypes, where percent black, median household income, and
percent below poverty were dropped and dual eligibility, median home value, percent below high
school had a small hazard ratio. By comparison, Philbin and others (2001) reported a decrease
in readmission as neighborhood income increased. Foraker and others (2011) reported that given
co-morbidity measured by CCI, the readmission or death hazard was higher for low socioeco-
nomic status patients. The present paper considered more detailed phenotypes in addition to
CCI suggested a relatively smaller impact of socioeconomic status. The difference in results is
possibly because co-morbidity may be on the causal pathway between socioeconomic status and
readmission or death. Adjusting for a detailed set of co-morbidities partially blocks the effect of
socioeconomic status. Percent Hispanic residents was negatively associated with readmission or
death. Percent occupied houses increased the risk of readmission or death, which was consistent
with the strong positive prediction by population density. Most ecological health variable showed
a small hazard ratio.
Black and other race groups had a lower hazard than white. Females had a lower hazard than
males, which was consistent with Roger and others (2004) that females had a higher survival rate
than males after heart failure. Age was associated with an increased hazard of readmission or
death, as expected.
The coefficient by month suggested a higher risk of readmission or death in cold seasons than
warm seasons, with a larger negative hazard ratio for summer indicators. The short-term read-
mission or death rate was decreasing over time, which was suggested by the negative hazard ratio
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of later years. The later calendar year being negatively associated with readmission risk may be
an indication of improved follow-up care for patients discharged from heart failure. Consistently,
(Roger and others, 2004) also suggests an improved heart failure survival rate over time.
4.2 Incorporating Time-Dependent Covariates
The analysis has two goals. First, the covariates serve as the risk predictors of the hazard of
heart failure-specific readmission. Second, all covariates other than PM2.5 serve as the potential
confounders of the association between PM2.5 and readmission, particularly time trend and area-
level covariates. The DAClin procedure is a variable selection technique to drop non-informative
confounders given the high dimensionality of confounders. This goal aligns with Belloni and
others (2014), which constructs separate penalized regressions for the propensity score model
and outcome regression model to identify confounders. We herein focused on building a penalized
regression for the outcome regression model.
We applied DAClin algorithm with K = 200 to this time-dependent survival dataset. The
procedure was paralleled on 10 Authentic AMD Little Endian @2.30GHz CPUs. The estimation
of β̂DAC with I = 2 took 36.5 hours, including the time of loading the datasets into memory. The
result suggests each 10 µg m−3 increase in daily PM2.5 was associated with 0.5% increase of risk
(95% confidence interval [0.3%, 0.7%]) adjusting for individual-level, area-level covariates, and
temperature. Because there is rare evidence on whether air pollution is associated with heart
failure-specific readmission or death among heart failure patients and it is rare to estimate the
health effect of daily air pollution using a time-dependent Cox model, this model provides a novel
approach to address a new research question. While evidence is rare on the association between
daily PM2.5 and heart failure-specific readmission, some studies used case-crossover design to
estimate the effect of short-term PM2.5 on the incidence of heart failure admissions. Pope and
others (2008) found that a 10 µg m−3 increase in 14-day moving average PM2.5 was associated
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with a 13.1% (1.3%, 26.2%) increase in the incidence of heart failure admissions among elderly
patients; Zanobetti and others (2009) reported that each 10 µg m−3 increase in 2-day averaged
PM2.5 was associated with a 1.85% (1.19%, 2.51%) increase in the incidence of congestive heart
failure admission. There is also a large body of literature suggesting that short-term exposure to
PM2.5 is associated with an increased risk of death. For example, (Di and others, 2017) shows
among the Medicare population during 2000 − 2012 that each 10 µg m−3 increase in PM2.5
was associated with an 1.05% (0.95%, 1.15%) increase in mortality risk. In addition, Figure 2
shows the covariate-specific estimates of the hazard ratio for all the covariates, with the estimates
consistent with the analysis of time-independent dataset.
5. Discussions
The proposed DAClin procedure for fitting adaptive LASSO penalized Cox model reduces the
computation cost, while it maintains the precision of estimation and accuracy in variable selection
with an extraordinarily large n0 and a numerically large p. The use of β˜DAC makes it feasible to
obtain the
√
n0-consistent estimator required by penalized step (e.g. when there is a constraint in
RAM) and shortens the computation time of the initial estimator by > 50%. The improvement
in the computation time was substantial in the regularized regression step. The LSA converted
the fitting of regularized regression from using a dataset of size n0 to a dataset of size p.
The majority voting-based method β̂MV with MCP (Chen and Xie, 2014) had a substantially
longer computation time than β̂full. The difference primarily comes from (a) the fact that the Cox
model with MCP is fitted K times and (b) the computation efficiency between glmnet algorithm
which is more efficient than the MCP algorithm in ncvsurv (Breheny and Huang, 2011).
The difference in variable selection between β̂DAC and β̂MV (Chen and Xie, 2014) is primarily
due to the majority voting. The simulations in Chen and Xie (2014) have shown that an increase
in the percentage for the majority voting decreased the sensitivity and increased the specificity
18 Y. Wang and others
of variable selection. Similarly in the simulations of the present study with a 50% of the majority
vote, Chen and Xie’s procedure showed a high specificity but the sensitivity was low for weaker
signals as demonstrated in the simulation studies.
For non-weak signals, the oracle property appears to hold well as evidenced by the simula-
tion results for β
(I)
0 and β
(II)
0 shown in Tables 3-4. For weak signals such as 0.035 in β
(III)
0 , the
oracle property does not appear to hold even with n0 = 1, 000, 000 and the bias in the shrinkage
estimators results in confidence intervals with low coverage. This is consistent with the the im-
possibility result shown in Potscher and Schneider (2009), which suggests difficulty in deriving
precise interval estimators when adaptive LASSO penalty is employed.
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6. Appendix
Throughout we assume all regularity conditions required in Zhang and Lu (2007), p is fixed
and β0 belongs to a compact support. We next establish the asymptotic equivalence of β˜DAC
and β˜Ωfull in that n
1
2
0 (β˜DAC − β˜Ωfull) = op(1). To this end, we note that ‖β˜Ω1 − β0‖ = Op(n−
1
2 ),
supt,β |Ŝr,Ωk(t,β) − Sr(t,β)| = Op(n−
1
2 ), and supt,β |Ŝr,DAC(t,β) − Sr(t,β)| = Op(n−
1
2
0 ), where
Ŝr,DAC(t,β) = K−1
∑K
k=1 Ŝr,Ωk(t,β). It follows that supβ ‖ÂDAC−A(β)‖ = Op(n
− 12
0 ). From a taylor
REFERENCES 19
series expansion, it’s straightforward to see that for k = 2, ...,K,
β˜Ωk,lin − β˜Ωk = Op(n−1) = op(n
− 12
0 ).
On the other hand, β˜Ωk − β0 = A(β0)−1ÛΩk(β0) +Op(n−1). Therefore,
β˜Ωk,lin − β0 = A(β0)−1ÛΩk(β0) +Op(n−1).
Furthermore, from the convergence rate of Ŝr,Ωk(t,β) and the fact that supt |n−1
∑
i∈Ωk Mi(t,β0)| =
Op(n
− 12 ), we have ÛΩk(β0)− U˜Ωk(β0) = Op(n−1), where
U˜Ω(β0) = n
−1
Ω
∑
i∈Ω
∫ {
Zi(t)− S1(t,β0)S0(t,β0)
}
dMi(t,β0).
It follows that
β˜Ωk,lin − β0 = A(β0)−1U˜Ωk(β0) +Op(n−1).
and therefore
β˜
[1]
DAC − β0 = A(β0)−1K−1
K∑
k=1
U˜Ωk(β0) +Op(n
−1) = A(β0)−1U˜Ωfull(β0) + op(n−
1
2 ).
Similarly, we may show that
β˜Ωfull − β0 = A(β0)−1ÛΩfull(β0) +Op(n−10 ) = A(β0)−1U˜Ωfull(β0) + op(n
− 12
0 ).
This implies that n
1
2
0 (β˜
[1]
DAC − β˜Ωfull) = op(1). Similar arguments can be used to show that the
equivalence holds for further iterations of β˜
[I]
DAC with I > 2. Although the asymptotic equivalence
holds even for I = 1, we find that I = 2 tends to give better approximation in finite samples.
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l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
1.
0
1.
5
2.
0
2.
5
Acute appendicitis
Viral Enteritis
Influenza
Peritoneal adhesions (postoperative) (postinfection)Palpitations
Calculus of ureterNonspecific chest pain
Viral infection
Dizziness and giddiness (Light−headedness and vertigo)Asthma with exacerbation
Incisional hernia
Syncope and collapsePainful respiration
Peritoneal or intestinal adhesions
Acute bronchitis and bronchiolitis
Bronchitis
Pneumococcal pneumonia
Other headache syndromesOrthostatic hypotension
Noninfectious gastroenteritisYear 2012 vs 2000
Chronic sinusitisYear 2011 vs 2000
Acute upper respiratory infections of multiple or unspecified sites
Secondary malignancy of lymph nodesTransient cerebral ischemia
Pyelonephritis
Asthma
Chronic kidney disease, Stage I or IIYear 2010 vs 2000
Calculus of bile ductCholelithiasis with acute cholecystitis
Calculus of kidneyYear 2009 vs 2000
Obstructive sleep apneaOther cardiomyopathy
Chronic bronchitisYear 2008 vs 2000
Gastrointestinal complicationsPortal hypertension
Sinoatrial node dysfunction (Bradycardia)Atherosclerosis of native arteries of the extremities with intermittent claudication
Umbilical hernia
Cardiac complications, not elsewhere classifiedVitamin D deficiency
Encounter for long−term (current) use of anticoagulantsBenign neoplasm of colon
Sleep apneaCellulitis and abscess of fingers/toes
Essential tremor
Inguinal herniaOther hypertensive complications
Barrett's esophagusChronic Kidney Disease, Stage III
Year 2007 vs 2000
Cholelithiasis with other cholecystitisHemorrhoids
CoughDiverticulosis
Vitamin B−complex deficiencies
Allergic rhinitisAtrioventricular block, complete
Diaphragmatic herniaMobitz II AV block
Phlebitis and thrombophlebitis
Chronic obstructive asthma with exacerbationAtopic/contact dermatitis due to other or unspecified
Poisoning by analgesics, antipyretics, and antirheumaticsBronchiectasis
Respiratory complications
Benign neoplasm of other parts of digestive systemFirst degree AV block
Neutropenia
Rhabdomyolysis
Esophageal bleeding (varices/hemorrhage)Displacement of intervertebral disc
Phlebitis and thrombophlebitis of lower extremitiesCystic kidney disease
E. coli
Irritable Bowel SyndromeUnspecified disorder of lipoid metabolism
Lack of coordination
Hyperlipidemia
Fracture of radius and ulna
Hypercholesterolemia
Secondary hypothyroidismCataract
Gram negative septicemiaHypertensive heart disease
Poisoning by water, mineral, and uric acid metabolism drugsDisorders of phosphorus metabolism
Conjunctivitis, infectiousPersonal history of allergy to medicinal agents
Ventral hernia
Osteoarthritis; localizedHemorrhage or hematoma complicating a procedure
Urinary incontinence
Chronic venous insufficiency [CVI]Non−black non−white vs white
Month 6 vs 1
Diverticulitis
ObesityBlack vs white
Acute posthemorrhagic anemiaYear 2006 vs 2000
Occlusion and stenosis of precerebral arteriesChronic obstructive asthma
Arthropathy NOSAnal and rectal conditions
Pain in limb
Percent Hispanic
Essential hypertension
Month 8 vs 1
Malignant neoplasm of rectum, rectosigmoid junction, and anusHyperplasia of prostate
Month 7 vs 1
Month 5 vs 1
Functional disorders of bladder
Osteopenia or other disorder of bone and cartilageMelanomas of skin, dx or hx
Cancer of prostateOpiates and related narcotics causing adverse effects in therapeutic use
Cardiac shunt/ heart septal defectAcute pancreatitis
Colon cancerEncounter for long−term (current) use of aspirin
Symptoms of the musclesRestless legs syndrome
Other non−epithelial cancer of skinMonth 4 vs 1
Lesions of stomach and duodenum
Hyperparathyroidism
Other diseases of lungMalignant neoplasm of kidney, except pelvis
Malignant neoplasm of female breastCardiac defibrillator in situ
Pulmonary collapse; interstitial and compensatory emphysema
Pernicious anemia
Nausea and vomitingMyalgia and myositis unspecified
Month 9 vs 1
GERDCancer of kidney and renal pelvis
Supraventricular premature beatsAngina pectoris
Reflux esophagitisDisorders of esophageal motility
Month 10 vs 1
Fever of unknown originGlaucoma
Second degree AV blockYear 2005 vs 2000
Varicose veins of lower extremity, symptomtic
Month 11 vs 1
Gouty arthropathyComplications of surgical and medical procedures
Other abnormal glucoseVentricular fibrillation and flutter
Insomnia
Degeneration of intervertebral discOsteoarthrosis NOS
Atrophic gastritisEncounter for long−term (current) use of antiplatelets/antithrombotics
Other specified cardiac dysrhythmiasSecondary hyperparathyroidism (of renal origin)
Rash and other nonspecific skin eruption
Fluid overload
Diarrhea
ContusionEmphysema
Angiodysplasia of intestine (without mention of hemorrhage)Cerebrovascular disease
Month 3 vs 1
Spinal stenosis of lumbar regionTobacco use disorder
Type 2 diabetes with renal manifestations
Other specified gastritisBronchopneumonia and lung abscess
Year 2001 vs 2000
Substance addiction and disordersMonth 12 vs 1
Noninfectious disorders of lymphatic channels
Bacterial infection NOSOther tests
Female vs male
Pain in jointSuperficial injury without mention of infection
Iron deficiency anemias, unspecified or not due to blood loss
Urinary complications NECDisorders of magnesium metabolism
Other peripheral nerve disordersExtrapyramidal disease and abnormal movement disorders
Spondylosis without myelopathyAllergy/adverse effect of penicillin
Cerebral atherosclerosisYear 2002 vs 2000
Hearing lossAbdominal aortic aneurysm
Poisoning/allergy of sulfonamidesPsoriasis vulgaris
Macular degeneration (senile) of retina NOSBladder neck obstruction
Nonrheumatic pulmonary valve disorders
Duodenitis
Disease of tricuspid valveTuberculosis
Dyspepsia and other specified disorders of function of stomach
Injury, NOSHeart failure NOS
Vascular dementia
Iatrogenic hypotensionHeart failure with preserved EF [Diastolic heart failure]
Regional enteritisGout
Osteoarthrosis, generalizedYear 2004 vs 2000
Other upper respiratory diseaseIron deficiency anemia secondary to blood loss (chronic)
Abnormality of gaitAphasia/speech disturbance
Atherosclerosis
Coronary atherosclerosisRight bundle branch block
Cellulitis and abscess of leg, except footStricture and stenosis of esophagus
Peptic ulcer, site unspecifiedAlcoholism
Gastric ulcerNonrheumatic tricuspid valve disorders
Cardiac pacemaker in situEsophagitis, GERD and related diseases
Year 2003 vs 2000
Overweight, obesity and other hyperalimentationSenile dementia
Alcohol−related disorders
Hypocalcemia
Atherosclerosis of aorta
Osteoporosis NOSDementias
Heart transplant/surgeryHypothyroidism NOS
Musculoskeletal symptoms referable to limbsObstructive chronic bronchitis
Month 2 vs 1
Gastritis and duodenitis, NOSOsteoarthrosis involving more than one site, but not specified as generalized
CardiomegalyPeripheral autonomic neuropathy
Pneumoconiosis
Hemorrhage from gastrointestinal ulcerEpilepsy, recurrent seizures, convulsions
Thyrotoxicosis with or without goiterStricture of artery
Epistaxis or throat hemorrhageDual eligibility
Premature beats
Acquired absence of breast
Fracture of ribs
Aneurysm and dissection of heart
Cellulitis and abscess of arm/handPostoperative infection
Ulcer of esophagusMalignant neoplasm of bladder
Percent having A1c testBacterial pneumonia
Complications of cardiac/vascular device, implant, and graftMalignant neoplasm of uterus
Chronic airway obstructionType 2 diabetes with neurological manifestations
Percent having ambulatory visitHypopotassemia
Median home value
Percent black
Median household income
Percent below poverty
H. pylori
Herpes zoster
Dermatophytosis of nail
Type 1 diabetes with ophthalmic manifestations
Type 2 diabetes with ophthalmic manifestationsAnemia in chronic kidney disease
Hereditary and idiopathic peripheral neuropathy
Myasthenia gravisHypertensive chronic kidney disease
Other forms of chronic heart diseaseChronic pulmonary heart disease
Chronic pericarditisHypertrophic obstructive cardiomyopathy
Paroxysmal supraventricular tachycardia
Arrhythmia (cardiac) NOSHemoptysis
ConstipationCystitis
Other disorders of bladderCellulitis and abscess of trunk
Unspecified osteomyelitisPolymyalgia Rheumatica
Spinal stenosisDifficulty in walking
Back pain
Edema
Malaise and fatigueVascular complications of surgery and medical procedures
Anticoagulants causing adverse effectsFracture of foot
Morbid obesity
Percent having LDL testsPercent below high school
Staphylococcus infectionsAtherosclerosis of renal artery
Heart valve replaced
Secondary/extrinsic cardiomyopathiesEmpyema and pneumothorax
Effects radiation NOSChronic pain
Kyphoscoliosis and scoliosis
CholangitisHerpes zoster with nervous system complications
Acute gastritisSarcoidosis
Methicillin sensitive Staphylococcus aureusShortness of breath
ASCVDOther open wound of head and face
Bundle branch block
Multiple sclerosis
Type 1 diabetes with renal manifestations
Abnormal electrocardiogram [ECG] [EKG]Diabetic retinopathy
Circulatory disease NECChronic renal failure [CKD]
Chronic glomerulonephritis, NOSAge
Blindness and low vision
CholelithiasisAdjustment reaction
ConvulsionsOther specified peripheral vascular diseases
Other venous embolism and thrombosisStreptococcus infection
Polyneuropathy in diabetes
Urinary obstruction
Diabetes type 2 with peripheral circulatory disorders
Cholecystitis without cholelithiasisDeficiency anemias
Left bundle branch block
Effects of other external causes
Alcoholic liver damageInfection/inflammation of internal prosthetic device; implant; and graft
Kyphosis (acquired)Cellulitis and abscess of foot, toe
Abdominal pain
Type 2 diabetes
Viral hepatitis CRetention of urine
Hallucinations
Hypertensive heart and/or renal diseaseLymphoid leukemia, chronic
Delirium due to conditions classified elsewhere
Acute pericarditisDysthymic disorder
Malignant neoplasm of ovaryType 1 diabetes with neurological manifestations
Ulcerative colitis
Mechanical complication of unspecified genitourinary device, implant, and graftParalytic ileus
Cirrhosis of liver without mention of alcoholPolycythemia vera
Anemia of chronic disease
Pulmonary embolism and infarction, acute
Adverse drug events and drug allergiesInsulin pump user
Atrial flutter
Alzheimer's disease
Depression
Other disorders of pancreatic internal secretionNonspecific abnormal findings in stool contents
Open wounds of extremitiesDuodenal ulcer
Vascular insufficiency of intestine
HydronephrosisBacteremia
Other disorders of liverChronic Kidney Disease, Stage IV
Osteoarthrosis, localized, primaryAsphyxia and hypoxemia
Aortic aneurysm
Lymphadenitis
Percent occupied housing unitPeripheral vascular disease, unspecified
CCISeptic shock
Mental retardation
Abnormal coagulation profileCongestive heart failure (CHF) NOS
Parkinson's disease
Late effects of cerebrovascular disease
Nephrotic syndrome without mention of glomerulonephritisOther diseases of blood and blood−forming organs
Giant cell arteritisAnxiety disorder
Mean BMI
Abnormal heart sounds
Deep vein thrombosis [DVT]Pyogenic arthritis
Pulmonary insufficiency or respiratory failure following trauma and surgeryCrushing or internal injury to organs
Hematuria
Dementia with cerebral degenerationsOther anemias
Fracture of humerus
Rheumatoid arthritis
Other chronic ischemic heart disease, unspecifiedSepsis
Hydrocephalus
Atherosclerosis of the extremities
Urinary tract infection
Dependence on respirator [Ventilator] or supplemental oxygenSpecific nonpsychotic mental disorders due to brain damage
Skull and face fracture and other intercranial injuryElevated white blood cell count
Other abnormal blood chemistryAplastic anemia
Adrenal hypofunctionForeign body injury
Peripheral angiopathy in diseases classified elsewherePrimary pulmonary hypertension
SchizophreniaThrombocytopenia
Fracture of pelvisOther disorders of stomach and duodenum
Other disorders of neurohypophysisNephritis and nephropathy in diseases classified elsewhere
Other CNS infection and poliomyelitisOther symptoms
Blood in stool
ShockSymptoms concerning nutrition, metabolism, and development
Other intestinal obstructionPrimary/intrinsic cardiomyopathies
Other dyspneaComplication of internal orthopedic device
Hypovolemia
Alkalosis
Type 1 diabetes
Pneumonia
Electrolyte imbalance
Cardiac rhythm regulators causing adverse effects in therapeutic useSystemic lupus erythematosus
Impaction of intestine
Renal dialysis
Nonrheumatic mitral valve disorders
GastroparesisHematemesis
Arterial embolism and thrombosis
Kidney replaced by transpantAcidosis
Psychosis
Bipolar
Altered mental status
Other pulmonary inflamation or edemaPericarditis
Peritonitis and retroperitoneal infections
Secondary thrombocytopeniaHeart failure with reduced EF [Systolic or combined heart failure]
Acute vascular insufficiency of intestine
PancytopeniaUnstable angina (intermediate coronary syndrome)
Other paralytic syndromesAphasia
Infection with drug−resistant microorganismsAtrial fibrillation
Complications of gastrostomy, colostomy and enterostomyAcquired coagulation factor deficiency
Paroxysmal ventricular tachycardia
Other and unspecified disorders of the nervous systemSmoking rate
Diseases of white blood cells
Other specified disorders of plasma protein metabolismOther persistent mental disorders due to conditions classified elsewhere
Abnormal serum enzyme levels
Pathologic fracture of vertebraeFracture of vertebral column without mention of spinal cord injury
Cancer of stomachAcid−base balance disorder
SepticemiaMRSA pneumonia
Other disorders of intestineHypotension NOS
Abnormal results of function study of liver
Tachycardia NOSPostinflammatory pulmonary fibrosis
Other and unspecified coagulation defectsHemorrhage of rectum and anus
Hyposmolality and/or hyponatremiaPseudomonal pneumonia
Hemorrhage of gastrointestinal tractCandidiasis
HyperpotassemiaComplication due to other implant and internal device
Chronic ulcer of leg or footPrimary thrombocytopenia
Hypotension
Pulmonary congestion and hypostasisFracture of unspecified part of femur
Secondary malignant neoplasmOther symptoms involving urinary system
Anemia in neoplastic disease
Mitral valve stenosis and aortic valve stenosis
Alteration of consciousness
Other disorders of the kidney and uretersEncephalopathy, not elsewhere classified
Anorexia
End stage renal diseaseKwashiorkor
Symptoms involving respiratory system and other chest symptomsMajor depressive disorder
Acute and subacute necrosis of liver
Pleurisy; pleural effusion
Nonrheumatic aortic valve disorders
Debility unspecified
Secondary malignant neoplasm of digestive systemsGram positive septicemia
Jaundice (not of newborn)Intestinal infection due to C. difficile
Mitral valve disease
Cardiogenic shockDysphagia
Secondary malignancy of boneHypercalcemia
Arterial embolism and thrombosis of lower extremity artery
Non−Hodgkins lymphomaMyeloproliferative disease
Other acute and subacute forms of ischemic heart diseaseAcute renal failure
Fracture of neck of femur
Protein−calorie malnutrition
Chronic passive congestion of liverSecondary malignancy of respiratory organs
Cardiac arrestOcclusion of cerebral arteries, with cerebral infarction
Idiopathic fibrosing alveolitisEndocarditis
Respiratory insufficiency
Liver abscess and sequelae of chronic liver disease
Myocardial infarction
Multiple myelomaAtherosclerosis of native arteries of the extremities with ulceration or gangrene
Cancer of esophagusCancer of bronchus; lung
Respiratory failure
HemiplegiaAcute, but ill−defined cerebrovascular disease
Secondary malignancy of brain/spineDecubitus ulcer
Pneumonitis due to inhalation of food or vomitus
severe protein−calorie malnutrition
Malignant neoplasm, otherCachexia
Ascites (non malignant)Renal failure NOS
Subdural hemorrhageOther conditions of brain
Hyperosmolality and/or hypernatremiaPancreatic cancer
Cerebral artery occlusion, with cerebral infarctionNutritional marasmus
Secondary malignant neoplasm of liverAdult failure to thrive
GangreneSubdural hemorrhage (injury)
Intracerebral hemorrhageMyeloid leukemia, acute
Population density
Hazard ratio
Fig. 1. Hazard ratios of each covariate predicting heart failure readmissions or death within 30 days after
the first admission using DAClin.
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Acute appendicitis
Viral Enteritis
Influenza
Peritoneal adhesions (postoperative) (postinfection)Calculus of ureter
Nonspecific chest painDizziness and giddiness (Light−headedness and vertigo)
PalpitationsViral infection
Incisional hernia
Syncope and collapseAsthma with exacerbation
Painful respiration
Peritoneal or intestinal adhesions
Acute bronchitis and bronchiolitis
Bronchitis
Pneumococcal pneumoniaOther headache syndromes
Orthostatic hypotensionNoninfectious gastroenteritis
Year 2012 vs 2000
Chronic sinusitisYear 2011 vs 2000
Secondary malignancy of lymph nodesAcute upper respiratory infections of multiple or unspecified sites
Transient cerebral ischemia
Asthma
PyelonephritisChronic kidney disease, Stage I or II
Year 2010 vs 2000
Cholelithiasis with acute cholecystitisCalculus of kidney
Calculus of bile ductPortal hypertension
Obstructive sleep apneaYear 2009 vs 2000
Other cardiomyopathyGastrointestinal complications
Year 2008 vs 2000
Chronic bronchitisSinoatrial node dysfunction (Bradycardia)
Atherosclerosis of native arteries of the extremities with intermittent claudication
Umbilical hernia
Cardiac complications, not elsewhere classifiedVitamin D deficiency
Encounter for long−term (current) use of anticoagulantsCellulitis and abscess of fingers/toes
Sleep apneaBenign neoplasm of colon
Inguinal herniaOther hypertensive complications
Chronic Kidney Disease, Stage IIIYear 2007 vs 2000
Cholelithiasis with other cholecystitisHemorrhoids
Diverticulosis
CoughVitamin B−complex deficiencies
Allergic rhinitisAtrioventricular block, complete
Mobitz II AV block
Chronic obstructive asthma with exacerbationDiaphragmatic hernia
Bronchiectasis
Phlebitis and thrombophlebitisAtopic/contact dermatitis due to other or unspecified
Respiratory complications
NeutropeniaFirst degree AV block
Esophageal bleeding (varices/hemorrhage)Rhabdomyolysis
Displacement of intervertebral discPhlebitis and thrombophlebitis of lower extremities
Cystic kidney diseaseE. coli
Lack of coordination
Unspecified disorder of lipoid metabolismIrritable Bowel Syndrome
Hyperlipidemia
Fracture of radius and ulna
Month 6 vs 1
HypercholesterolemiaCataract
Gram negative septicemiaHypertensive heart disease
Secondary hypothyroidismPoisoning by water, mineral, and uric acid metabolism drugs
Conjunctivitis, infectiousDisorders of phosphorus metabolism
Ventral hernia
Benign neoplasm of other parts of digestive systemHemorrhage or hematoma complicating a procedure
Osteoarthritis; localizedChronic venous insufficiency [CVI]
Urinary incontinence
Month 8 vs 1
Month 7 vs 1
Non−black non−white vs white
Black vs white
Diverticulitis
ObesityPercent Hispanic
Acute posthemorrhagic anemiaMonth 5 vs 1
Occlusion and stenosis of precerebral arteriesChronic obstructive asthma
Arthropathy NOSYear 2006 vs 2000
Malignant neoplasm of rectum, rectosigmoid junction, and anusPain in limb
Essential hypertensionHyperplasia of prostate
Anal and rectal conditions
Functional disorders of bladder
Cancer of prostateOsteopenia or other disorder of bone and cartilage
Melanomas of skin, dx or hx
Month 4 vs 1
Opiates and related narcotics causing adverse effects in therapeutic useColon cancer
Cardiac shunt/ heart septal defectAcute pancreatitis
Month 9 vs 1
Symptoms of the musclesEncounter for long−term (current) use of aspirin
Restless legs syndromeMalignant neoplasm of kidney, except pelvis
HyperparathyroidismOther non−epithelial cancer of skin
Malignant neoplasm of female breastLesions of stomach and duodenum
Cardiac defibrillator in situPulmonary collapse; interstitial and compensatory emphysema
Other diseases of lungNausea and vomiting
Myalgia and myositis unspecifiedMonth 10 vs 1
Cancer of kidney and renal pelvisGERD
Supraventricular premature beatsFever of unknown origin
Angina pectorisReflux esophagitis
GlaucomaDisorders of esophageal motility
Month 11 vs 1
Pernicious anemia
Second degree AV blockYear 2005 vs 2000
Gouty arthropathyComplications of surgical and medical procedures
Other abnormal glucoseInsomnia
Ventricular fibrillation and flutter
Atrophic gastritisOsteoarthrosis NOS
Degeneration of intervertebral discSecondary hyperparathyroidism (of renal origin)
Encounter for long−term (current) use of antiplatelets/antithromboticsOther specified cardiac dysrhythmias
Rash and other nonspecific skin eruptionFluid overload
Diarrhea
ContusionEmphysema
Month 3 vs 1
Cerebrovascular diseaseAngiodysplasia of intestine (without mention of hemorrhage)
Type 2 diabetes with renal manifestations
Bronchopneumonia and lung abscessTobacco use disorder
Spinal stenosis of lumbar regionMonth 12 vs 1
Substance addiction and disordersYear 2001 vs 2000
Other specified gastritisOther tests
Noninfectious disorders of lymphatic channelsBacterial infection NOS
Varicose veins of lower extremity, symptomticFemale vs male
Pain in jointSuperficial injury without mention of infection
Urinary complications NECOther peripheral nerve disorders
Iron deficiency anemias, unspecified or not due to blood lossExtrapyramidal disease and abnormal movement disorders
Disorders of magnesium metabolismSpondylosis without myelopathy
Cerebral atherosclerosisAllergy/adverse effect of penicillin
Year 2002 vs 2000
Abdominal aortic aneurysm
Hearing lossPoisoning/allergy of sulfonamides
Psoriasis vulgarisBladder neck obstruction
Nonrheumatic pulmonary valve disordersMacular degeneration (senile) of retina NOS
Tuberculosis
Vascular dementia
Duodenitis
Disease of tricuspid valveDyspepsia and other specified disorders of function of stomach
Iatrogenic hypotensionHeart failure NOS
Osteoarthrosis, generalizedHeart failure with preserved EF [Diastolic heart failure]
GoutRegional enteritis
Other upper respiratory diseaseYear 2004 vs 2000
Abnormality of gaitIron deficiency anemia secondary to blood loss (chronic)
Aphasia/speech disturbanceAtherosclerosis
Stricture and stenosis of esophagusGastric ulcer
Coronary atherosclerosisOverweight, obesity and other hyperalimentation
Right bundle branch blockCellulitis and abscess of leg, except foot
Peptic ulcer, site unspecified
Nonrheumatic tricuspid valve disordersSenile dementia
Alcoholism
Esophagitis, GERD and related diseasesCardiac pacemaker in situ
Year 2003 vs 2000
Alcohol−related disorders
Atherosclerosis of aorta
Heart transplant/surgeryDementias
Osteoporosis NOSMusculoskeletal symptoms referable to limbs
Obstructive chronic bronchitisHypothyroidism NOS
Month 2 vs 1
Osteoarthrosis involving more than one site, but not specified as generalizedGastritis and duodenitis, NOS
Pneumoconiosis
Stricture of arteryHypocalcemia
CardiomegalyPeripheral autonomic neuropathy
Hemorrhage from gastrointestinal ulcerThyrotoxicosis with or without goiter
Epilepsy, recurrent seizures, convulsionsAcquired absence of breast
Epistaxis or throat hemorrhageAneurysm and dissection of heart
Fracture of ribs
Premature beats
Dual eligibilityCellulitis and abscess of arm/hand
Malignant neoplasm of bladderPostoperative infection
Type 2 diabetes with neurological manifestationsComplications of cardiac/vascular device, implant, and graft
Bacterial pneumoniaChronic airway obstruction
Percent having A1c testUlcer of esophagus
Polymyalgia RheumaticaHypopotassemia
Hypertensive chronic kidney diseaseMyasthenia gravis
Percent having ambulatory visitCellulitis and abscess of trunk
Median home value
Temperature lag0Median household income
Percent below povertyH. pylori
Herpes zosterDermatophytosis of nail
Malignant neoplasm of uterusType 1 diabetes with ophthalmic manifestations
Type 2 diabetes with ophthalmic manifestationsAnemia in chronic kidney disease
Hereditary and idiopathic peripheral neuropathyOther forms of chronic heart disease
Chronic pericarditisHypertrophic obstructive cardiomyopathy
Paroxysmal supraventricular tachycardiaHemoptysis
ConstipationCystitis
Other disorders of bladderUnspecified osteomyelitis
Spinal stenosisDifficulty in walking
Edema
Anticoagulants causing adverse effectsPersonal history of allergy to medicinal agents
Temperature lag0, squaredDew Point Temperature lag0, squared
Dew Point Temperature lag0PM2.5 lag0
Percent black
Chronic pulmonary heart diseasePercent having LDL tests
Percent below high schoolBack pain
Malaise and fatigueVascular complications of surgery and medical procedures
Injury, NOSMorbid obesity
Arrhythmia (cardiac) NOSHeart valve replaced
Atherosclerosis of renal artery
Staphylococcus infectionsEmpyema and pneumothorax
Secondary/extrinsic cardiomyopathiesFracture of foot
Kyphoscoliosis and scoliosisEffects radiation NOS
Acute gastritisMethicillin sensitive Staphylococcus aureus
ASCVDShortness of breath
Bundle branch block
Other open wound of head and faceChronic pain
Chronic renal failure [CKD]Age
Circulatory disease NECAbnormal electrocardiogram [ECG] [EKG]
Chronic glomerulonephritis, NOSDiabetic retinopathy
ConvulsionsBlindness and low vision
CholelithiasisOther venous embolism and thrombosis
SarcoidosisMultiple sclerosis
Type 1 diabetes with renal manifestations
Streptococcus infectionOther specified peripheral vascular diseases
Essential tremor
Diabetes type 2 with peripheral circulatory disordersUrinary obstruction
Left bundle branch block
Deficiency anemias
Infection/inflammation of internal prosthetic device; implant; and graftPolyneuropathy in diabetes
Alcoholic liver damageEffects of other external causes
Cholecystitis without cholelithiasisKyphosis (acquired)
Cellulitis and abscess of foot, toeAbdominal pain
Type 2 diabetesHypertensive heart and/or renal disease
Viral hepatitis CRetention of urine
Adjustment reactionHallucinations
Lymphoid leukemia, chronicDelirium due to conditions classified elsewhere
Type 1 diabetes with neurological manifestationsAcute pericarditis
Malignant neoplasm of ovaryDysthymic disorder
Cirrhosis of liver without mention of alcoholUlcerative colitis
Mechanical complication of unspecified genitourinary device, implant, and graftParalytic ileus
Herpes zoster with nervous system complicationsAnemia of chronic disease
Pulmonary embolism and infarction, acute
Adverse drug events and drug allergiesAtrial flutter
Insulin pump userAlzheimer's disease
Polycythemia vera
DepressionNonspecific abnormal findings in stool contents
Other disorders of pancreatic internal secretionDuodenal ulcer
Vascular insufficiency of intestine
HydronephrosisOpen wounds of extremities
Bacteremia
Chronic Kidney Disease, Stage IVOther disorders of liver
Osteoarthrosis, localized, primaryAsphyxia and hypoxemia
Peripheral vascular disease, unspecifiedAortic aneurysm
CCILymphadenitis
Septic shockPercent occupied housing unit
Congestive heart failure (CHF) NOSAbnormal coagulation profile
Mean BMI
Late effects of cerebrovascular disease
Parkinson's disease
Other diseases of blood and blood−forming organsAnxiety disorder
Mental retardation
Nephrotic syndrome without mention of glomerulonephritisDeep vein thrombosis [DVT]
Giant cell arteritisAbnormal heart sounds
Pulmonary insufficiency or respiratory failure following trauma and surgeryCrushing or internal injury to organs
Hematuria
Other anemiasFracture of humerus
Dementia with cerebral degenerationsRheumatoid arthritis
Other chronic ischemic heart disease, unspecifiedAtherosclerosis of the extremities
SepsisHydrocephalus
Urinary tract infection
Dependence on respirator [Ventilator] or supplemental oxygenSpecific nonpsychotic mental disorders due to brain damage
Elevated white blood cell count
Aplastic anemiaOther abnormal blood chemistry
Skull and face fracture and other intercranial injuryPeripheral angiopathy in diseases classified elsewhere
Foreign body injuryAdrenal hypofunction
Primary pulmonary hypertensionPoisoning by analgesics, antipyretics, and antirheumatics
SchizophreniaThrombocytopenia
Other disorders of stomach and duodenumNephritis and nephropathy in diseases classified elsewhere
Other disorders of neurohypophysisFracture of pelvis
Other symptomsShock
Blood in stool
Symptoms concerning nutrition, metabolism, and developmentPrimary/intrinsic cardiomyopathies
Other intestinal obstructionHypovolemia
Other dyspneaAlkalosis
Complication of internal orthopedic deviceType 1 diabetes
Pneumonia
Electrolyte imbalance
Cardiac rhythm regulators causing adverse effects in therapeutic useSystemic lupus erythematosus
Impaction of intestineNonrheumatic mitral valve disorders
Renal dialysis
Hematemesis
GastroparesisKidney replaced by transpant
Acidosis
Psychosis
Arterial embolism and thrombosis
Other pulmonary inflamation or edemaPericarditis
Peritonitis and retroperitoneal infections
Secondary thrombocytopeniaBipolar
Altered mental status
Pyogenic arthritisHeart failure with reduced EF [Systolic or combined heart failure]
Acute vascular insufficiency of intestine
PancytopeniaOther CNS infection and poliomyelitis
Unstable angina (intermediate coronary syndrome)Other paralytic syndromes
Infection with drug−resistant microorganismsAphasia
Atrial fibrillation
Complications of gastrostomy, colostomy and enterostomyAcquired coagulation factor deficiency
Paroxysmal ventricular tachycardia
Smoking rateOther and unspecified disorders of the nervous system
Diseases of white blood cells
Other specified disorders of plasma protein metabolismOther persistent mental disorders due to conditions classified elsewhere
Abnormal serum enzyme levels
Pathologic fracture of vertebraeCancer of stomach
Fracture of vertebral column without mention of spinal cord injuryAcid−base balance disorder
SepticemiaOther disorders of intestine
MRSA pneumoniaHypotension NOS
Tachycardia NOSOther and unspecified coagulation defects
Abnormal results of function study of liver
Postinflammatory pulmonary fibrosisHemorrhage of rectum and anus
Hyposmolality and/or hyponatremiaHemorrhage of gastrointestinal tract
Pseudomonal pneumoniaComplication due to other implant and internal device
CandidiasisHyperpotassemia
Chronic ulcer of leg or footHypotension
Pulmonary congestion and hypostasisSecondary malignant neoplasm
Other symptoms involving urinary systemPrimary thrombocytopenia
Fracture of unspecified part of femur
Anemia in neoplastic diseaseMitral valve stenosis and aortic valve stenosis
Other disorders of the kidney and uretersAlteration of consciousness
Encephalopathy, not elsewhere classifiedAnorexia
End stage renal diseaseKwashiorkor
Symptoms involving respiratory system and other chest symptomsMajor depressive disorder
Acute and subacute necrosis of liver
Pleurisy; pleural effusion
Nonrheumatic aortic valve disorders
Debility unspecifiedSecondary malignant neoplasm of digestive systems
Gram positive septicemiaJaundice (not of newborn)
Intestinal infection due to C. difficileMitral valve disease
Cardiogenic shockSecondary malignancy of bone
DysphagiaHypercalcemia
Arterial embolism and thrombosis of lower extremity artery
Non−Hodgkins lymphomaMyeloproliferative disease
Acute renal failure
Other acute and subacute forms of ischemic heart diseaseProtein−calorie malnutrition
Fracture of neck of femur
Secondary malignancy of respiratory organsChronic passive congestion of liver
Cardiac arrestOcclusion of cerebral arteries, with cerebral infarction
Idiopathic fibrosing alveolitisEndocarditis
Respiratory insufficiencyLiver abscess and sequelae of chronic liver disease
Myocardial infarction
Multiple myelomaAtherosclerosis of native arteries of the extremities with ulceration or gangrene
Cancer of esophagusCancer of bronchus; lung
Respiratory failureHemiplegia
Acute, but ill−defined cerebrovascular disease
Secondary malignancy of brain/spineDecubitus ulcer
Pneumonitis due to inhalation of food or vomitus
severe protein−calorie malnutritionMalignant neoplasm, other
Ascites (non malignant)Cachexia
Renal failure NOSOther conditions of brain
Hyperosmolality and/or hypernatremiaPancreatic cancer
Cerebral artery occlusion, with cerebral infarctionNutritional marasmus
Subdural hemorrhageSecondary malignant neoplasm of liver
Adult failure to thrive
GangreneSubdural hemorrhage (injury)
CholangitisIntracerebral hemorrhage
Barrett's esophagusMyeloid leukemia, acute
Population density
Hazard ratio
Fig. 2. Hazard ratios of each covariate in estimating hazard of heart failure readmissions or death within
30 days associated with PM2.5 after the first admission using DAClin.
26 REFERENCES
Table 1. Comparisons of β˜DAC I = 1, 2, 3 and β˜Ωfull with respect to average computation time in
seconds and global mean squared error (GMSE ×10−5) for the estimation of β(I)0 , β(II)0 , and β(III)0
using time-independent survival data.
β0 = β
(I)
0 β0 = β
(II)
0 β0 = β
(III)
0
v Estimator Time GMSE Time GMSE Time GMSE
p = 50
0.2 I = 1 5.9 19.32 5.0 21.10 5.4 21.20
β˜DAC I = 2 11.5 19.29 9.6 21.10 10.5 21.20
I = 3 17.1 19.29 14.2 21.10 15.6 21.20
β˜Ωfull 26.5 19.21 22.6 21.03 24.9 21.13
0.5 I = 1 5.6 18.10 6.3 19.51 5.7 20.40
β˜DAC I = 2 10.8 18.06 12.2 19.49 11.0 20.39
I = 3 16.0 18.06 18.2 19.49 16.4 20.39
β˜Ωfull 29.1 17.99 31.5 19.44 25.6 20.35
0.8 I = 1 6.6 17.91 6.6 18.69 5.7 19.73
β˜DAC I = 2 12.8 17.83 12.9 18.66 11.2 19.72
I = 3 19.0 17.83 19.1 18.66 16.6 19.72
β˜Ωfull 33.3 17.74 32.7 18.60 29.2 19.65
p = 200
0.2 I = 1 79.1 74.94 73.2 83.81 69.4 85.02
β˜DAC I = 2 155.1 74.48 143.3 83.36 135.5 84.61
I = 3 231.2 74.48 213.9 83.36 201.4 84.61
β˜Ωfull 377.7 74.29 300.9 83.16 284.9 84.41
0.5 I = 1 88.8 68.99 81.3 76.47 72.1 80.63
β˜DAC I = 2 173.8 68.31 158.8 76.06 141.4 80.25
I = 3 258.9 68.31 236.3 76.06 210.7 80.25
β˜Ωfull 415.8 68.12 387.6 75.86 299.8 80.07
0.8 I = 1 92.9 65.96 86.3 72.03 76.0 77.25
β˜DAC I = 2 181.5 65.02 168.7 71.53 148.6 76.85
I = 3 269.3 65.03 251.3 71.53 221.1 76.85
β˜Ωfull 485.9 64.85 405.1 71.34 357.4 76.65
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Table 2. Comparisons of β˜DAC I = 1, 2, 3 and β˜Ωfull with respect to average computation time in
seconds and global mean squared error (GMSE ×10−5) for the estimation of β(IV)0 using time-
dependent survival data.
β0 = β
(IV)
0
v Estimator Time GMSE
0.2 I = 1 62.0 17.94
β˜DAC I = 2 120.8 17.93
I = 3 178.7 17.93
β˜Ωfull 262.1 17.95
0.5 I = 1 58.0 17.88
β˜DAC I = 2 112.2 17.88
I = 3 166.3 17.88
β˜Ωfull 263.4 17.88
0.8 I = 1 58.3 17.98
β˜DAC I = 2 113.8 17.98
I = 3 168.5 17.98
β˜Ωfull 253.8 17.94
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Table 3. Comparisons of β̂DAC (I = 1, 2, 3), β̂full, and β̂MV for estimating β0 = β(I)0 with respect
to average computation time in seconds, GMSE (×10−5), coefficient-specific empirical probabil-
ity (%) of j 6∈ Â, bias (×10−4), MSE (×10−5), and empirical coverage probability (%) of the
confidence intervals.
v = 0.2 v = 0.5 v = 0.8
β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV
I = 1 2 3 1 2 3 1 2 3
p = 50
Time 5.9 11.6 17.1 469.5 2140.6 5.6 10.8 16.1 485.5 1001.0 6.7 12.9 19.0 515.3 1077.5
GMSE 4.32 4.27 4.27 4.24 5.61 4.53 4.42 4.42 4.41 7.40 5.17 5.01 5.01 4.97 9.91
0.8 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -0.74 0.49 0.49 0.63 12.87 -1.64 -0.24 -0.24 -0.19 12.30 -0.27 1.16 1.16 1.16 14.71
MSE 0.55 0.55 0.55 0.55 0.72 0.70 0.70 0.70 0.70 0.86 1.50 1.50 1.50 1.50 1.76
CovP 94.9 95.7 95.7 - - 95.0 95.3 95.3 - - 96.2 96.4 96.4 - -
0.4 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -1.47 -0.85 -0.85 -0.72 5.61 -0.63 0.07 0.07 0.03 6.55 -0.02 0.72 0.72 0.73 8.81
MSE 0.49 0.48 0.48 0.48 0.52 0.55 0.55 0.55 0.55 0.60 1.48 1.48 1.48 1.46 1.60
CovP 93.8 94.3 94.3 - - 97.3 97.1 97.1 - - 95.7 95.7 95.7 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -1.39 -1.09 -1.09 -1.18 2.75 -0.82 -0.49 -0.49 -0.44 3.88 -3.37 -3.02 -3.02 -2.87 -3.18
MSE 0.44 0.44 0.44 0.44 0.46 0.63 0.63 0.63 0.63 0.67 1.49 1.48 1.48 1.48 1.76
CovP 95.0 94.9 94.9 - - 95.1 95.1 95.1 - - 96.0 96.1 96.1 - -
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
p = 200
Time 79.3 155.3 231.4 1539.0 21029.7 89.0 174.0 259.0 1684.9 4256.8 93.1 181.6 269.5 1664.5 4814.5
GMSE 4.62 4.10 4.10 4.08 5.50 5.83 4.61 4.61 4.61 9.50 6.91 5.05 5.05 5.06 17.02
0.8 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -5.46 0.31 0.31 0.27 13.21 -6.75 0.25 0.25 0.33 16.02 -6.38 0.94 0.94 0.84 20.72
MSE 0.58 0.53 0.53 0.53 0.71 0.77 0.70 0.70 0.70 0.97 1.49 1.45 1.45 1.45 1.96
CovP 94.5 95.2 95.2 - - 95.0 96.0 96.0 - - 96.3 96.2 96.2 - -
0.4 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -2.09 0.80 0.80 0.81 7.88 -3.11 0.29 0.29 0.43 8.89 -3.47 0.24 0.24 0.57 11.37
MSE 0.45 0.44 0.44 0.44 0.51 0.68 0.66 0.66 0.66 0.76 1.42 1.42 1.42 1.42 1.62
CovP 95.5 96.2 96.2 - - 95.6 95.2 95.2 - - 96.0 95.8 95.8 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -4.15 -2.68 -2.68 -2.69 0.40 -4.15 -2.44 -2.44 -2.52 3.63 -2.02 -0.15 -0.15 -0.09 1.09
MSE 0.44 0.43 0.43 0.43 0.45 0.61 0.60 0.60 0.60 0.61 1.34 1.33 1.33 1.33 1.62
CovP 96.0 96.5 96.5 - - 95.5 95.8 95.8 - - 97.1 97.1 97.1 - -
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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Table 4. Comparisons of β̂DAC (I = 1, 2, 3), β̂full, and β̂MV for estimating β0 = β(II)0 with respect
to average computation time in seconds, GMSE (×10−5), coefficient-specific empirical probabil-
ity (%) of j 6∈ Â, bias (×10−4), MSE (×10−5), and empirical coverage probability (%) of the
confidence intervals.
v = 0.2 v = 0.5 v = 0.8
β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV
I = 1 2 3 1 2 3 1 2 3
p = 50
Time 5.0 9.6 14.2 440.1 2147.8 6.3 12.3 18.2 479.8 1223.6 6.6 12.9 19.2 505.4 1133.0
GMSE 7.27 7.24 7.24 7.22 869.51 6.92 6.86 6.86 6.84 1176.14 7.21 7.12 7.12 7.17 4451.57
0.4 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 1.14 1.59 1.59 1.60 97.75 1.47 2.07 2.07 2.11 109.82 4.82 5.45 5.45 1.39 218.73
MSE 0.53 0.53 0.53 0.53 10.11 0.71 0.71 0.71 0.71 12.83 1.70 1.70 1.70 1.68 49.58
CovP 95.1 95.1 95.1 - - 95.6 95.5 95.5 - - 95.2 95.3 95.3 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 0.72 0.94 0.94 1.14 98.26 1.61 1.90 1.90 2.02 107.74 3.63 3.95 3.95 1.06 205.50
MSE 0.50 0.50 0.50 0.50 10.19 0.76 0.76 0.76 0.75 12.43 1.65 1.65 1.65 1.66 44.21
CovP 95.5 95.7 95.7 - - 95.5 95.4 95.4 - - 95.9 96.1 96.1 - -
0.05 %zero 0.0 0.0 0.0 0.0 61.6 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -4.21 -4.16 -4.16 -4.21 -406.64 -5.65 -5.55 -5.55 -5.52 -500.00 -11.40 -11.31 -11.31 -7.22 -500.00
MSE 0.50 0.50 0.50 0.49 179.49 0.71 0.71 0.71 0.70 250.00 2.08 2.07 2.07 2.05 250.00
CovP 95.2 95.2 95.2 - - 94.8 94.9 94.9 - - 91.5 91.7 91.7 - -
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00
p = 200
Time 73.4 143.5 214.1 1435.0 20459.8 81.5 159.0 236.5 1560.5 4646.5 86.5 168.9 251.5 1666.2 5056.3
GMSE 7.53 7.29 7.29 7.28 1496.27 7.58 7.05 7.05 7.03 1300.22 8.38 7.46 7.46 7.67 12696.30
0.4 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -0.02 2.00 2.00 2.07 138.62 0.84 3.59 3.59 3.58 125.20 5.70 8.81 8.81 0.58 171.68
MSE 0.54 0.54 0.54 0.54 19.78 0.80 0.79 0.79 0.79 16.53 1.62 1.67 1.67 1.62 31.19
CovP 95.4 94.9 94.9 - - 94.8 94.9 94.9 - - 96.3 96.2 96.2 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -0.02 0.99 0.99 1.08 142.42 0.15 1.59 1.59 1.77 122.19 3.94 5.37 5.37 5.56 151.36
MSE 0.49 0.49 0.49 0.49 20.82 0.75 0.75 0.75 0.74 15.76 1.72 1.73 1.73 1.79 25.05
CovP 96.4 96.4 96.4 - - 95.4 95.2 95.2 - - 95.1 95.3 95.3 - -
0.05 %zero 0.0 0.0 0.0 0.0 99.1 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -6.39 -6.07 -6.07 -6.08 -498.29 -8.32 -7.92 -7.92 -7.83 -500.00 -18.45 -18.11 -18.11 -15.39 -500.00
MSE 0.59 0.57 0.57 0.57 248.62 0.84 0.82 0.82 0.82 250.00 2.38 2.38 2.38 2.43 250.00
CovP 93.6 93.2 93.2 - - 93.1 93.5 93.5 - - 90.5 91.0 91.0 - -
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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Table 5. Comparisons of β̂DAC (I = 1, 2, 3), β̂full, and β̂MV for estimating β0 = β(III)0 when p = 50
with respect to average computation time in seconds, GMSE (×10−5), coefficient-specific empirical
probability (%) of j 6∈ Â, bias (×10−4), MSE (×10−5), and empirical coverage probability (%) of
the confidence intervals.
v = 0.2 v = 0.5 v = 0.8
β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV
I = 1 2 3 1 2 3 1 2 3
p = 50
Time 5.4 10.5 15.7 416.4 1975.2 5.7 11.1 16.4 409.6 1511.2 5.8 11.2 16.6 419.2 805.4
GMSE 5.36 5.35 5.35 5.33 1154.39 5.17 5.14 5.14 5.13 1261.31 5.70 5.67 5.67 5.65 3144.68
1 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 1.70 2.78 2.78 2.90 149.35 2.24 3.55 3.55 3.69 177.28 11.68 13.06 13.05 11.39 261.71
MSE 0.67 0.68 0.68 0.68 23.00 0.91 0.91 0.91 0.91 32.44 2.07 2.10 2.10 2.05 70.53
CovP 95.0 95.0 95.0 - - 94.9 94.7 94.7 - - 94.9 94.7 94.7 - -
0.5 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 2.54 3.06 3.06 3.14 158.85 4.90 5.53 5.53 5.71 177.87 13.53 14.22 14.22 13.60 258.65
MSE 0.54 0.54 0.54 0.54 25.80 0.77 0.78 0.78 0.78 32.53 1.94 1.96 1.96 1.94 68.80
CovP 95.0 95.0 95.0 - - 94.8 94.8 94.8 - - 94.8 94.4 94.4 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 2.02 2.26 2.26 2.36 162.72 2.00 2.21 2.21 2.39 174.73 7.91 8.17 8.17 8.50 244.46
MSE 0.55 0.55 0.55 0.54 27.10 0.73 0.73 0.73 0.73 31.42 1.91 1.91 1.91 1.92 61.97
CovP 94.8 95.0 95.0 - - 96.1 96.0 96.0 - - 94.7 94.7 94.7 - -
0.1 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.1
Bias -0.73 -0.60 -0.60 -0.55 -66.80 1.57 1.71 1.71 1.92 58.13 5.84 5.99 5.99 6.77 -390.41
MSE 0.51 0.51 0.51 0.51 5.75 0.65 0.65 0.65 0.65 5.25 1.84 1.85 1.85 1.86 307.51
CovP 95.8 95.6 95.6 - - 96.7 96.4 96.4 - - 95.0 95.1 95.1 - -
0.05 %zero 0.0 0.0 0.0 0.0 80.1 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -3.27 -3.22 -3.22 -3.15 -451.64 -2.92 -2.85 -2.85 -2.77 -500.00 -7.17 -7.13 -7.13 -6.80 -500.00
MSE 0.53 0.53 0.53 0.53 213.48 0.81 0.81 0.81 0.81 250.00 2.05 2.05 2.05 2.03 250.00
CovP 94.2 94.1 94.1 - - 95.0 95.0 95.0 - - 94.0 93.9 93.9 - -
0.035 %zero 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -4.72 -4.67 -4.67 -4.57 -350.00 -6.74 -6.66 -6.66 -6.64 -350.00 -17.13 -17.07 -17.07 -15.98 -350.00
MSE 0.55 0.55 0.55 0.55 122.50 0.83 0.83 0.83 0.83 122.50 2.29 2.29 2.29 2.23 122.50
CovP 94.8 94.8 94.8 - - 94.0 93.9 93.9 - - 92.1 92.1 92.1 - -
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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Table 6. Comparisons of β̂DAC (I = 1, 2, 3), β̂full, and β̂MV for estimating β0 = β(III)0 when p = 200
with respect to average computation time in seconds, GMSE (×10−5), coefficient-specific empirical
probability (%) of j 6∈ Â, bias (×10−4), MSE (×10−5), and empirical coverage probability (%) of
the confidence intervals.
v = 0.2 v = 0.5 v = 0.8
β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV β̂DAC β̂full β̂MV
I = 1 2 3 1 2 3 1 2 3
p = 200
Time 69.6 135.7 201.5 1339.0 19425.3 72.3 141.5 210.9 1381.1 3121.6 76.2 148.7 221.3 1393.8 3788.2
GMSE 5.53 5.38 5.38 5.37 1438.17 5.70 5.45 5.45 5.44 1377.06 6.68 6.27 6.27 6.25 8328.95
1 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -0.78 3.84 3.84 3.90 186.92 2.03 7.72 7.72 7.90 197.72 14.18 20.69 20.69 17.61 195.98
MSE 0.67 0.68 0.68 0.68 35.63 0.87 0.91 0.91 0.92 40.12 2.05 2.29 2.29 2.16 40.41
CovP 95.4 95.1 95.1 - - 95.5 94.6 94.6 - - 95.3 94.1 94.1 - -
0.5 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 2.06 4.46 4.46 4.56 205.74 5.67 8.47 8.47 8.64 197.18 17.50 20.60 20.60 19.01 186.32
MSE 0.50 0.51 0.51 0.51 42.85 0.77 0.81 0.81 0.81 39.75 2.19 2.28 2.28 2.20 36.67
CovP 96.3 96.4 96.4 - - 95.4 94.6 94.6 - - 93.2 92.8 92.8 - -
0.2 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 0.73 1.64 1.64 1.73 203.39 4.57 5.63 5.63 5.81 195.00 14.72 15.90 15.90 15.74 162.90
MSE 0.46 0.46 0.46 0.46 41.94 0.74 0.74 0.74 0.74 38.86 1.92 1.94 1.94 1.94 28.81
CovP 96.8 96.6 96.6 - - 96.1 96.1 96.1 - - 95.3 94.5 94.5 - -
0.1 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 88.5
Bias 0.77 1.30 1.30 1.43 -198.61 3.40 4.01 4.01 4.34 -19.37 6.65 7.27 7.28 8.22 -906.50
MSE 0.48 0.48 0.48 0.48 40.82 0.75 0.75 0.75 0.75 3.09 1.82 1.81 1.81 1.83 889.22
CovP 96.0 95.9 95.9 - - 95.4 95.6 95.6 - - 94.9 95.2 95.2 - -
0.05 %zero 0.0 0.0 0.0 0.0 99.9 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -4.72 -4.44 -4.44 -4.35 -499.81 -5.54 -5.21 -5.21 -5.03 -500.00 -11.07 -10.82 -10.82 -10.27 -500.00
MSE 0.51 0.50 0.50 0.50 249.85 0.81 0.80 0.80 0.80 250.00 2.17 2.15 2.15 2.14 250.00
CovP 95.1 95.2 95.2 - - 94.4 94.5 94.5 - - 93.5 93.4 93.4 - -
0.035 %zero 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 100.0
Bias -9.70 -9.55 -9.55 -9.54 -350.00 -10.90 -10.66 -10.66 -10.63 -350.00 -29.87 -29.37 -29.37 -27.09 -350.00
MSE 0.63 0.63 0.63 0.63 122.50 0.98 0.97 0.97 0.97 122.50 3.36 3.30 3.30 3.16 122.50
CovP 93.6 93.4 93.4 - - 92.8 93.3 93.3 - - 87.2 86.8 86.9 - -
0 %zero 99.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
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Table 7. Performance of β̂DAC (I = 1, 2, 3) and β̂full,lin for estimating β0 = β(IV)0 with respect to av-
erage computation time in seconds, GMSE (×10−5), coefficient-specific empirical probability (%)
of j 6∈ Â, bias (×10−4), MSE (×10−5), and empirical coverage probability (%) of the confidence
intervals.
v = 0.2 v = 0.5 v = 0.8
β̂DAC β̂full,lin β̂DAC β̂full,lin β̂DAC β̂full,lin
I = 1 2 3 1 2 3 1 2 3
Time 62.0 120.8 178.8 262.1 58.0 112.3 166.4 263.5 58.3 113.8 168.6 253.9
GMSE 3.55 3.55 3.55 3.55 3.68 3.68 3.68 3.69 4.44 4.44 4.44 4.44
pind = 50
0.08 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 1.45 1.46 1.46 1.46 4.62 4.63 4.63 4.65 11.91 11.93 11.93 12.04
MSE 0.22 0.22 0.22 0.22 0.36 0.36 0.36 0.36 1.02 1.02 1.02 1.03
CovP 95.7 95.7 95.7 95.8 94.6 94.6 94.6 94.7 93.9 93.9 93.9 93.5
0.04 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -0.19 -0.19 -0.19 -0.14 0.53 0.54 0.54 0.61 3.45 3.47 3.47 3.45
MSE 0.22 0.22 0.22 0.22 0.33 0.33 0.33 0.33 0.93 0.93 0.93 0.93
CovP 95.4 95.5 95.5 95.5 96.0 96.1 96.1 96.0 93.7 93.8 93.8 93.7
0.02 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -4.55 -4.56 -4.56 -4.58 -6.79 -6.78 -6.78 -6.89 -17.43 -17.42 -17.42 -17.21
MSE 0.25 0.25 0.25 0.25 0.45 0.45 0.45 0.45 1.59 1.59 1.59 1.57
CovP 94.1 94.1 94.1 94.4 90.5 90.8 90.8 90.8 86.8 86.7 86.7 86.8
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
pdep = 50
0.08 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias 1.01 1.01 1.01 1.04 2.65 2.65 2.65 2.61 9.72 9.74 9.74 9.74
MSE 0.21 0.21 0.21 0.21 0.37 0.37 0.37 0.38 0.93 0.93 0.93 0.95
CovP 96.3 96.3 96.3 96.3 94.6 94.6 94.6 94.4 95.6 95.5 95.5 95.4
0.04 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -1.01 -1.01 -1.01 -1.01 1.11 1.11 1.11 1.15 3.26 3.26 3.26 3.19
MSE 0.21 0.21 0.21 0.21 0.33 0.33 0.33 0.33 0.93 0.93 0.93 0.94
CovP 95.8 95.9 95.9 96.0 95.2 95.2 95.2 95.3 94.9 94.8 94.8 95.0
0.02 %zero 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Bias -3.81 -3.81 -3.81 -3.81 -6.28 -6.26 -6.26 -6.30 -16.47 -16.47 -16.47 -16.59
MSE 0.26 0.26 0.26 0.25 0.45 0.45 0.45 0.45 1.49 1.48 1.48 1.49
CovP 93.8 93.8 93.8 93.5 91.2 91.1 91.1 91.4 86.2 86.1 86.1 86.0
0 %zero 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Bias 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
MSE 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
